Medical Esthetics Sponsored by
Editor’s Note: The opinions expressed in this article are those of the author and not necessarily those of Merge magazine.
Abstract: Changes in regulations for corporate-sponsored presentations may present ethical dilemmas for physicians, requiring careful consideration and due diligence when accepting a speaking engagement.
As physicians, we are often invited to speak on behalf of pharmaceutical companies or device manufacturers. These invitations are typically presented to those who use a particular product with great success or are well-recognized and respected by their peers for publications, research, surgical prowess or other accomplishments.
Until relatively recently, physicians invited to give presentations on behalf of corporate entities manufacturing drugs or devices were given the latitude to present any information they felt was pertinent. Slide decks created by the sponsoring vendor were usually made available to presenters for use at their discretion, and the presenting physicians could opt to utilize as many or as few of the slides provided as they wished, possibly even supplementing their own slide additions.
In January 2009, however, the Pharmaceutical Research and Manufacturers of America (PhRMA) dramatically changed the manner in which pharmaceutical companies interact with physicians, introducing an updated Code on Interaction with Healthcare Professionals. In an effort to be compliant with this updated code, pharmaceutical companies have enacted numerous requirements that directly affect corporate-sponsored physician presentations.